LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (drug combination treatments). Dataset 1 of 2: Cell count and normalized growth rate inhibition values. - Dataset - HMS LINCS Database

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (drug combination treatments). Dataset 1 of 2: Cell count and normalized growth rate inhibition values. - Dataset (ID:20259)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 19 of 139
Next
>>
>
451 to 475 of 3455 records
per page:

Cell	Small Molecule	Small Mol 1 Concentration	Small Mol 1 Conc Unit	Small Molecule 2	Small Mol 2 Concentration	Small Mol 2 Conc Unit	Biological Replicate	Technical Replicate	Total Cell Count Before Treatment	Total Cell Count After Treatment	Total Control Cell Count	Normalized Growth Rate Inhibition Value
BT-20	Dactolisib	0.0137	uM	Saracatinib	0.3704	uM	1	2	2751	3078	4996	0.1393
BT-20	Dactolisib	0.0412	uM	NVP-TAE684	1.1111	uM	1	2	2751	3085	4996	0.1423
BT-20	Alpelisib	0.0400	uM	Trametinib	0.3704	uM	1	2	2751	4304	4996	0.6818
BT-20	Alpelisib	10	uM	Trametinib	0.3704	uM	1	2	2751	349	4996	-0.9091
BT-20	Alpelisib	10	uM	Neratinib	0.1235	uM	1	2	2751	464	4996	-0.8735
BT-20	Dactolisib	0.3704	uM	Neratinib	0.3704	uM	1	2	2751	1172	4996	-0.6289
BT-20	Dactolisib	0.3704	uM	Lapatinib	5.7735	uM	1	2	2751	2355	4996	-0.1652
BT-20	Alpelisib	1.1111	uM	Lapatinib	10	uM	1	2	2751	1342	4996	-0.5656
BT-20	Dactolisib	0.3704	uM	Trametinib	0.3704	uM	1	2	2751	763	4996	-0.7746
BT-20	Saracatinib	1.9245	uM		0	uM	1	2	2751	4439	4996	0.7432
BT-20	Dactolisib	0.3704	uM	Trametinib	3.3333	uM	1	2	2751	663	4996	-0.8085
BT-20	Dactolisib	0.0412	uM	Neratinib	0.2138	uM	1	2	2751	1608	4996	-0.4641
BT-20	Alpelisib	0.3704	uM	Selumetinib	3.3333	uM	1	2	2751	2761	4996	0.0042
BT-20	Dactolisib	0.0137	uM	Lapatinib	10	uM	1	2	2751	3167	4996	0.1776
BT-20		0	uM		0	uM	1	2	2751	5008	4996	1.0053
BT-20	Dactolisib	0.3704	uM	Lapatinib	3.3333	uM	1	2	2751	2208	4996	-0.2255
BT-20	Alpelisib	0.3704	uM	Selumetinib	1.1111	uM	1	2	2751	3751	4996	0.4335
BT-20	Alpelisib	1.1111	uM		0	uM	1	2	2751	3184	4996	0.1850
BT-20	Alpelisib	0.3704	uM	Neratinib	0.2138	uM	1	2	2751	2070	4996	-0.2814
BT-20	Alpelisib	10	uM	Neratinib	0.6415	uM	1	2	2751	390	4996	-0.8966
BT-20	Alpelisib	10	uM	Saracatinib	1.9245	uM	1	2	2751	389	4996	-0.8969
BT-20	Alpelisib	0.1235	uM	Saracatinib	1.1111	uM	1	2	2751	3989	4996	0.5397
BT-20	Alpelisib	0.0400	uM	Lapatinib	5.7735	uM	1	2	2751	5251	4996	1.1188
BT-20	Dactolisib	0.0047	uM	Saracatinib	3.3333	uM	1	2	2751	4196	4996	0.6328
BT-20	Alpelisib	0.0400	uM	Trametinib	1.1111	uM	1	2	2751	4020	4996	0.5536

|<
<<
Previous
Page 19 of 139
Next
>>
>
451 to 475 of 3455 records
per page:

HMS LINCS Project

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (drug combination treatments). Dataset 1 of 2: Cell count and normalized growth rate inhibition values. - Dataset (ID:20259)